CSF1R and breast carcinoma: For instance, a phase Ib/II study evaluating the combination of the CSF-1R inhibitor, pexidartinib, with pembrolizumab in advanced solid tumors, including HR+ breast cancer, demonstrated enhanced T-cell infiltration and a partial response in a subset of patients [36].